StockNews.com assumed coverage on shares of Oragenics (NYSE:OGEN – Free Report) in a research report report published on Saturday morning. The brokerage issued a sell rating on the stock.
Oragenics Stock Performance
NYSE OGEN opened at $0.34 on Friday. The stock’s 50 day moving average is $0.64 and its 200 day moving average is $1.13. Oragenics has a twelve month low of $0.29 and a twelve month high of $7.74.
Oragenics (NYSE:OGEN – Get Free Report) last announced its earnings results on Friday, August 9th. The company reported ($0.51) EPS for the quarter.
Institutional Trading of Oragenics
About Oragenics
Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.
Further Reading
- Five stocks we like better than Oragenics
- What is the Nasdaq? Complete Overview with History
- How Verizon Could Offer Stress-Free Double-Digit Returns in 2025
- How to Invest in Small Cap StocksĀ
- Can Roche Challenge Lilly and Novo in the Weight Loss Market?
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- Roblox Stock: Key Metrics Surge, Is This the Perfect Entry?
Receive News & Ratings for Oragenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oragenics and related companies with MarketBeat.com's FREE daily email newsletter.